World Federation of Hemophilia
-
Global dosing hold in fitusiran trials initiated by Sanofi Genzyme to investigate new adverse events
A joint statement of the World Federation of Hemophilia (WFH), European Haemophilia Consortium (EHC) and National Hemophilia Foundation (NHF) November 6, 2020 – The WFH,...
-
Enrollment in gene therapy trials on hold for assessment of interim data: Takeda
Takeda has suspended screening and further enrollment in the clinical studies of its AAV8 gene therapies for the treatment of hemophilia A and B. The...
-
Latifa Lamhene and Baiba Ziemele co-opted to WFH Board of Directors
The World Federation of Hemophilia (WFH) 2020 Annual Meeting of the General Assembly was held on October 16, and saw the election of a new...
-
rHEALTH point-of-care device gets NIH support
rHEALTH announced on October 8, 2020 that it was awarded a $1.5 million USD “Direct to Phase II” grant from the National Institutes of Health (NIH)...
-
Roche outlines plan for communicating new findings on emicizumab (Hemlibra)
In a letter to the global hemophilia community, Roche describes its plan for keeping healthcare professionals and patients informed of new efficacy and safety data...
-
WFH Advisory: availability of desmopressin pending re-start of intranasal desmopressin manufacture
Update to WFH Notice: Global recall of Octim®/Octostim® desmopressin nasal spray (1.5 mg/ml) by Ferring Pharmaceuticals With ongoing investigation following the mid-July global recall of...
-
Roche/Genentech Update on Particles Identified in emicizumab (Hemlibra)
Roche and Genentech have announced an update on measures being taken in relation to the translucent silicon oil and protein particles that were identified in...
-
Update on FDA approval for valoctocogene roxaparvovec gene therapy for severe hemophilia A
A statement was released by BioMarin regarding the status of the U.S. Food and Drug Administration (FDA) approval process for valoctocogene roxaparvovec gene therapy for...
-
WFH Notice: Global recall of Octim®/Octostim® desmopressin nasal spray (1.5 mg/ml) by Ferring Pharmaceuticals
Update to WFH Notice: recall of desmopressin nasal spray by Ferring Pharmaceuticals (July 20, 2020) August 4, 2020 In mid-July, Ferring Pharmaceuticals initiated a voluntary precautionary...
-
WFH Notice: recall of desmopressin nasal spray by Ferring Pharmaceuticals
July 20, 2020 The WFH has learned of a voluntary product recall of desmopressin nasal spray by Ferring Pharmaceuticals, due to out of specification results...
